Latest Videos Archives

Practical Considerations for the Use of Molecular Diagnostics for Diagnosis and Management of Recurrent UTI

Posted by Ngoc-Bich "Nikki" Phan Le, MD | Jun 2020

Ngoc-Bich “Nikki” Phan Le, MD, a urologist specializing in female pelvic medicine and reconstructive surgery at the Austin Diagnostic Clinic, and A. Lenore Ackerman, MD, PhD, Assistant Professor of Surgery, Urology, and Pelvic Medicine and Reconstructive Surgery at Cedars-Sinai Medical Center and Section Editor of the Next Generation Microbiome and Urologic Infection Learning Center on Grand Rounds in Urology, discuss how to effectively use molecular diagnostics to help in the process of diagnosing and managing recurrent UTIs. They outline the differences between patients with multiple types of infections over time and those with truly recurrent infections by the same bacterium, and how this difference creates the need for alternatives in initial evaluation. They also specifically detail how the strength of molecular diagnostics is in their ability to detect bacteria missed in cultures, which can help prescribers make better decisions when choosing antibiotics for treatment. Drs. Le and Ackerman conclude by discussing how to proceed with treatment, and how the data presented by molecular diagnostics allow for more precise treatment methods.

Phase 1 Trial of ARV-110 in Patients with mCRPC

Posted by Daniel P. Petrylak, MD | Jun 2020

Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center, discusses promising new developments coming out of a trial that interferes with the androgen receptor and degrades it. Phase 1 of this trial looks at ARV-110 in patients with mCRPC and Dr. Petrylak highlights why the study’s recent findings are so exciting. He goes into detail the study methodology and how ARV-110 works in comparison to traditional treatments. Dr. Petrylak also explains why the findings are so promising and what the next steps are for the study.

Anti-Androgen Trials

Posted by Daniel P. Petrylak, MD | Jun 2020

Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center, gives an overview of the most important, recent anti-androgen trials, as well as those that are currently still underway. He highlights how the trials were conducted, what the researchers found, and what he feels is still missing from the research. Dr. Petrylak compares and contrasts the different studies and draws conclusions about each. He also goes over a couple of trials with novel anti-androgens with unique mechanisms of action, which are currently in phase 1, that are showing promise.

HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer

Posted by Neal D. Shore, MD | Jun 2020

Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center, presents the key aspects of the HERO phase 3 trial. The Hero trial looked at Relugolix, an oral GnRH receptor antagonist, versus Leuprolide Acetate for the treatment of advanced prostate cancer. Following this in an interview with Celestia S. Higano, MD, section editor of the ADT Next Generation Learning Center on Grand Rounds in Urology, about the study’s findings, and the implications that this exciting new development in prostate cancer treatment could have in the field of urology.

Panel on Androgen Deprivation Therapy: A Closer Review of the Cardiovascular Risk

Posted by Thomas E. Keane, MD | Jun 2020

Thomas E. Keane, MD, Professor and Chairman of the Department of Urology at the Medical University of South Carolina, Charleston, leads a panel discussion including Lawrence I. Karsh, MD, Peter J. Rossi, MD, and Neal D. Shore, MD, FACS, to discuss the process of treating prostate cancer in a patient who is at risk for cardiovascular disease and how extra care is needed in such cases. They also stress the importance of being in contact with a patient’s PCP even if one chooses to do their own assessment of patient risk, as well as when ADT should not be considered an option, such as in the case of a patient with significant CAD and elevated liver enzymes. The group, over the course of the panel, discuss the many ADT options available, including their strengths and weaknesses.